Cardiovascularrisk associated with abnormal metabolism of plasma lipoproteins in patients with diabetes mellitus;Ryzyko sercowo-naczyniowe zwia̧zane z nieprawidłowym metabolizmem lipoprotein osocza u chorych na cukrzycȩ

Kardiologia Polska

Volumn 70, Issue 6, 2012, Pages 618-621

  Burchardt, Paweł ^a   Zawada, Agnieszka ^a   Wierusz Wysocka, Bogna ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN; ACETYL COENZYME A; HOMOSTEROID; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

CARDIOVASCULAR RISK; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; DISORDERS OF LIPOPROTEIN METABOLISM; HUMAN; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SHORT SURVEY; BLOOD; DIABETIC CARDIOMYOPATHY; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK FACTOR;

ACETYL COENZYME A; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; HOMOSTEROIDS; HUMANS; LIPOPROTEINS; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MITOCHONDRIA; RISK FACTORS; TRIGLYCERIDES;

EID: 84863758137     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (29)

1. Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J, 2007; 28: 2375-2414.
2. Adiels M, Olofsson SO, Taskinen MR, Borén J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol, 2008; 28: 1225-1236.
3. Adiels M, Taskinen MR, Borén J. Fatty liver, insulin resistance, and dyslipidemia. Curr Diab Rep, 2008; 8: 60-64. (Pubitemid 351384877)
4. Ginsberg HN, Zhang YL, Hernandez-Ono A. Metabolic syndrome: focus on dyslipidemia. Obesity, 2006; 14: 41S-49S.
5. Ferré P, Foufelle F. SREBP-1c transcription factor and lipid homeostasis: clinical perspective. Horm Res, 2007; 68: 72-82. (Pubitemid 47026704)
6. Iizuka K, Horikawa Y. ChREBP: a glucose-activated transcription factor involved in the development of metabolic syndrome. Endocr J, 2008; 55: 617-624.
7. Burchardt P, Wiktorowicz K, Goździcka-Józefiak A, Parucki R, Wysocki H. Disturbances in mitochondrial biosynthesis of acetyl-CoA and their role in the prevention of ischemic heart disease-review article. Kardiol Pol, 2008; 66: 1215-1220.
8. Verges B. New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabetes Metab, 2005; 31: 429-439.
9. Cooper AD. Hepatic uptake of chylomicron remnants. J Lipid Res, 1997; 38: 2173-2192. (Pubitemid 27495377)
10. Yamashita S, Hirano K, Sakai N, Matsuzawa Y. Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein. Biochim Biophys Acta, 2000; 1529: 257-275.
11. Zambon A, Bertocco S, Vitturi N, Polentarutti V, Vianello D, Crepaldi G. Relevance of hepatic lipase to the metabolism of triacylglycerol-rich lipoproteins. Biochem Soc Trans, 2003; 31: 1070-1074. (Pubitemid 37305048)
12. Alipour A, van Oostrom AJ, Izraeljan A et al. Leukocyte activation by triglyceride-rich lipoproteins. Arterioscler Thromb Vasc Biol, 2008; 28: 792-797. (Pubitemid 351651339)
13. Yoshida H, Kisugi R. Mechanisms of LDL oxidation. Clin Chimica Acta, 2010; 411: 23-24, 1875-1882.
14. Itabe H. Oxidative modification of LDL. Its pathological role in atherosclerosis. Clin Rev Allerg Immunol, 2009; 37: 4-11.
15. Mertens A, Hobvoet P. Oxidized and HDL: antagonists in atherothrombosis. FASEB J, 2001; 15: 2073-2084.
16. Adachi H, Tsujimoto M. Endothelial scavenger receptors. Progress Lipid Res, 2006; 45: 379-404.
17. Younis NN, Soran H, Sharma R et al. Small-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and non-statin-treated type 2 diabetes. Diab Vasc Dis Res, 2010; 7: 289-229.
18. Arca M. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. Drugs, 2007; 67 (suppl. 1): 43-54.
19. Ridker PM, Danielson E, Fonseca FA et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet, 2009; 373: 1175-1182.
20. Athyros VG, Tziomalos K, Karagiannis A. Mikhailidis DP. Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. Open Cardiovasc Med J, 2011; 5: 24-34.
21. Manuel-Y-Keenoy B, Van Campenhout C, Vertommen J, De Leeuw I. Effects of Atorvastatin on LDL sub-fractions and peroxidation in type 1 diabetic patients: a randomised double-blind placebo-controlled study. Diabetes Metab Res Rev, 2003; 19: 478-486.
22. Bilz S, Wagner S, Schmitz M, Bedynek A, Keller U, Demant T. Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. J Lipid Res, 2004; 45: 174-185. (Pubitemid 38176628)
23. Burchardt P, Kubacki T, Żurawski J, Żuchowski B, Wysocki H. Differences in lipid parameters among statins treated patients, due to coronary arteriosclerosis - pilot study. Eur J Lipid Science Technol, DOI:10.1002/ejlt.201100260.
24. Jacobson TA. Myopathy with statin-fibrate combination therapy: clinical considerations. Nat Rev Endocrinol, 2009; 5: 507-518.
25. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med, 2010; 10.1056/NEJMoa1001282.
26. Karakas M, Koenig W. Lp-PLA2 inhibition - the atherosclerosis panacea? Pharmaceuticals, 2010; 3: 1360-1373.
27. Cannon CP, Shah S, Dansky HM et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med, 2010; 363: 2406-2415.
28. Nicholls SJ, Gordon A, Johansson J et al. Efficacy and safety of a novel oral inducer of apolipoprotein A-I synthesis in statin-treated patients with stable coronary disease. J Am Coll Cardiol, 2011; doi:10.1016/j.jacc.2010.11. 015.
29. Whitney EJ, Krasuski RA, Personius BE et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med, 2005; 142: 95-104.